Optimizing outcomes for children and young adults with relapse of B-cell acute lymphoblastic leukemia after CD19-targeted chimeric antigen receptor T-cell therapy
NATIONAL CANCER INSTITUTE
· United States · $1.8M USD
We use cookies to keep your session secure, remember your preferences, and analyse site traffic with Google Analytics.
By continuing to use GrantFunds you agree to our
Privacy Policy
and
Terms of Use.